NCT01423812View on ClinicalTrials.gov

DRIVESHAFT: Darunavir/Ritonavir In HIV-infected Virologically-suppressed Experienced Subjects

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

May 31, 2014

Study Completion Date

April 30, 2015

Conditions
HIV
Interventions
DRUG

Twice-daily combination Darunavir and ritonavir

Subjects randomized 1:1 to remain on regimens containing combination Darunavir 600mg plus Ritonavir 100mg twice-daily

DRUG

Once-daily combination Darunavir and ritonavir

Subjects randomized 1:1 to switch to from combination Darunavir 600mg plus Ritonavir 100mg twice-daily at baseline to the experimental combination Darunavir 800mg plus Ritonavir 100mg once-daily for 48 weeks

Trial Locations (1)

60612

Ruth M. Rothstein CORE Center, Chicago

All Listed Sponsors
collaborator

Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

INDUSTRY

lead

Ruth M. Rothstein CORE Center

OTHER

NCT01423812 - DRIVESHAFT: Darunavir/Ritonavir In HIV-infected Virologically-suppressed Experienced Subjects | Biotech Hunter | Biotech Hunter